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Background: Several components of overall lung carcinogenesis, 
carcinogen metabolic and DNA repair pathways may be involved in 
individual genetic susceptibility to lung cancer.
Methods: We evaluated the role of cytochrome P450 (CYP) 1A1 
rs4646903 and rs104894, glutathione S-transferase (GST) M1 and 
GSTT1 deletion polymorphisms, GSTP1 rs1695, x-ray repair, excision 
repair cross-complementing group 2 (ERCC2) rs13181, complementing 
defective in Chinese hamster 1 rs25487, and XRCC3 rs861539 in a case-
control study comprising 462 lung cancer cases and 379 controls in a 
Japanese population. Unconditional logistic regression was used to assess 
the adjusted odds ratios (oR) and 95% confidence intervals (95% CI).
Results: CYP1A1 rs4646903 (oR = 1.72, 95% CI = 1.25–2.38), 
rs1048943 (oR = 1.40, 95% CI = 1.02–1.92), the GSTM1 deletion 
polymorphism (oR = 1.38, 95% CI = 1.01–1.89), GSTP1 rs1695 (oR 
=1.48, 95% CI = 1.04–2.11), ERCC2 rs13181 (oR = 1.89, 95% CI 
= 1.28–2.78), and Chinese hamster 1 rs25487 (oR = 1.54, 95% CI = 
1.12–2.13) were associated with lung cancer risk whereas the GSTT1 
deletion polymorphism and XRCC3 rs861539 were not. A pertinent 
combination of multiple “at-risk” genotypes of CYP1A1 rs4646903, 
the GSTM1 deletion polymorphism and ERCC2 rs13181 was at a 
5.94-fold (95% CI = 2.77–12.7) increased risk of lung cancer.
Conclusions: A pertinent combination of multiple at-risk genotypes 
may detect a high-risk group. Further studies are warranted to verify 
our findings.
Key Words: Carcinogen metabolism, DNA repair, Epidemiology, 
Genetic polymorphism, Lung cancer.
(J Thorac Oncol. 2012;7: 954–962)
Lung cancer is a major cause of cancer-related death in developed countries, and the overall survival rate is still 
extremely poor. Although tobacco smoking is an established 
risk factor for lung cancer, approximately one in 10 smokers 
develops lung cancer in their lifetime, indicating an interindi-
vidual variation in susceptibility to tobacco smoke.1
Various DNA alterations can be caused by exposure to 
tobacco smoke and environmental and endogenous carcino-
gens. Cells with damaged DNA are usually destroyed through 
apoptosis; however, aberrant cells may escape normal growth 
control and acquired mutations may alter apoptosis, thereby 
allowing for the development of lung cancer.2 Carcinogenesis 
therefore requires multiple genetic changes, as can occur 
within the context of long-term, repeated exposure to carci-
nogenic compounds.3,4 Furthermore, individuals may have a 
unique combination of polymorphic traits that modify genetic 
susceptibility and response to environmental carcinogens. 
Such carcinogens must be metabolically activated to exert their 
deleterious effects by phase-I enzymes such as those encoded 
by the cytochrome P450 (CYP) supergene family, but this is 
counteracted by the ongoing detoxification of carcinogens by 
phase-II enzymes such as those encoded by the glutathione 
S-transferases (GST) supergene family.5 Therefore, DNA dam-
age itself is a balance between activation and detoxification of 
carcinogens that involve phase-I and -II metabolic enzymes, 
many of which are polymorphic. The capacity to repair DNA 
damage induced by activated carcinogens is also a host factor 
that may influence lung cancer risk.6 Numerous epidemiologi-
cal studies suggest that genetic polymorphisms involved in 
activation, detoxification, and DNA repair are associated with 
increased risk of developing lung cancer.7,8 Identifying meta-
bolic and DNA-repair polymorphisms involved with exposure 
to carcinogens will help clarify the process by which lung can-
cer develops, and may thus indirectly lead to prevention.
Candidate-susceptibility genes for lung cancer have 
been extensively studied, with most of the work focus-
ing on mechanistically plausible polymorphisms in genes 
coding for enzymes involved in the activation, detoxi-
fication, and DNA repair of damage caused by tobacco 
smoke. Alterations in these pathways are hypothesized to 
affect an individual’s processing of tobacco carcinogens 
and therefore their risk of developing lung cancer. Thus it 
is expected that pertinent components of lung carcinogen-
esis may be involved in individual genetic susceptibility to 
tobacco-smoke exposure. As CyP1A1, GSTM1, GSTT1, 
GSTP1, excision repair cross-complementing group 2 (ERCC2), 
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x-ray repair complementing defective in Chinese hamster 
1 (XRCC1), and XRCC3 enzymes are involved in the 
tobacco-smoke carcinogenesis process, the genes, which 
code for these enzymes, have been of considerable inter-
est as candidate-susceptibility genes for lung cancer.5 As a 
functional polymorphism alters the expression of a gene or 
the structure/function of the gene product, a functional poly-
morphism may have some direct and/or immediate clinical 
relevance. CYP1A1 rs4646903 and rs1048943,9 GSTM1 and 
GSTT1 deletion polymorphisms, GSTP1 rs1695,10–12 ERCC2 
rs13181,13,14 XRCC1 rs2548715,16 and XRCC3 rs86153917 are 
potentially functional. The aim of this study is to assess the 
possible association of genetic polymorphisms in genes 
coding metabolic activation (CYP1A1 rs4646903 and 
rs1048943), detoxification (GSTM1, GSTT1 deletion poly-
morphisms, and GSTP1 rs1695) and DNA-repair enzymes 
(ERCC2 rs13181 in the nucleotide excision repair (NER) 
pathway, XRCC1 rs25487 in the base excision repair (BER) 
pathway, and XRCC3 rs861539 in the double-strand break 
repair (DSBR) pathway in pertinent components of overall 
lung carcinogenesis.
PATIENTS AND METHODS
Study Subjects and Data Collection
Lung cancer patients were recruited at Kyushu University 
Hospital (Research Institute for Diseases of the Chest, Kyushu 
University, Japan) and its collaborating hospitals. Eligible 
cases were newly diagnosed, and histologically confirmed 
primary lung cancer cases from 1996 to 2008 were selected. 
Histological types were categorized into four major types 
according to the International Classification of Diseases for 
oncology (ICD-o), second edition: adenocarcinoma (8140, 
8211, 8230–8231, 8250–8260, 8323, 8480–8490, 8550–8560, 
8570–8572), squamous cell carcinoma (8050–8076), small-
cell carcinoma (8040–8045) and large-cell carcinoma (8012–
8031, 8310). The participation rate among the cases was 100%. 
Potential controls (379) were selected from inpatients without 
a clinical history of any type of cancer, past or present, isch-
emic heart disease or chronic respiratory diseases, who were 
admitted to departments other than the departments of respi-
ratory medicine in collaborating hospitals during the same 
period because hospital controls are more motivated and are 
more easily accessible for DNA samples. Controls were not, 
individually or in larger groups, matched to cases. Controls 
were approached by their attending physicians to be recruited 
as control subjects. None of the controls refused to participate 
in this study. A self-administered questionnaire was used to 
collect data on demographic and lifestyle factors such as age, 
years of education, smoking, alcohol consumption, environ-
mental tobacco exposure from spouse, etc. All subjects were 
unrelated ethnic Japanese. The study protocol was approved 
by our institutional review board, and all participants provided 
written informed consent.
Genetic Analyses
Genomic DNA was extracted from blood samples. 
Genotyping was conducted with blinding to case/control 
status. The CYP1A1 rs4646903 and rs1048943 polymor-
phisms were genotyped by the methods described by 
Hayashi et al.18 and Nakachi et al.,19 respectively. The 
GSTM1 and GSTT1 deletion polymorphisms were deter-
mined by the methods described by Zhong et al.20 and 
Chenevix-Trench et al.,21 respectively. The genotyping of 
ERCC2 rs13181, XRCC1 rs25487, and XRCC3 rs861539 
was performed using the method described by Matullo et 
al.17 For quality control, both assays were repeated ran-
domly on 5% of all samples, and the replicates were 100% 
concordant.
Statistical Analysis
Comparisons of means and proportions were based on 
unpaired t test and χ2 test, respectively. The distribution of 
the CYP1A1 rs4646903, CYP1A1 rs1048943, GSTP1 rs1695, 
ERCC2 rs13181, XRCC1 rs25487 or XRCC3 rs861539 gen-
otypes in controls was compared with that expected from 
Hardy-Weinberg equilibrium (HWE) by the χ2 (Pearson) 
test, and linkage disequilibrium (LD) was assessed with D’ 
and r2. HWE was not tested for GSTM1 and GSTT1 dele-
tion polymorphisms because the genotyping methods we 
employed did not distinguish between non-null heterozy-
gotes and non-null homozygotes. We hypothesized that lung 
cancer patients would carry more active alleles (CYP1A1), 
null activity alleles (GSTM1, GSTT1), and less active alleles 
(GSTP1, ERCC2, XRCC1, XRCC3) than the control subjects. 
Unconditional logistic regression was used to compute the 
odds ratios (oRs) and their 95% confidence intervals (CIs), 
with adjustments for several covariates (age, sex, smoking 
status, drinking status, and education) found to be associated 
with risk.
Subjects were considered current-smokers if they had 
smoked or stopped smoking less than 1 year before either 
the date of diagnosis (lung cancer patients) or the date of 
completion of the questionnaires (controls). Nonsmokers 
were defined as those who had never smoked in their life-
time. Former-smokers were those who had stopped smoking 
1 or more years before either the date of diagnosis of lung 
cancer (lung cancer patients) or the date of completion of 
the questionnaires (controls). Based on “Healthy Japan 21” 
(National Health Promotion in the 21st Century), heavy drink-
ers were defined as those who drank more than 60 g of alcohol 
per day.22 As “Healthy Japan 21” has emphasized drinking an 
appropriate volume of alcohol (20 g of alcohol per day), appro-
priate drinkers were defined as those who did not exceed 20 g 
of alcohol intake per day. The appropriate volume of alcohol 
use may have a protective effect on life expectancy and mor-
bidity.23 Moderate drinkers were defined as those who drank 
more than 20 g alcohol per day but not exceeding 60 g per day. 
Unlike cigarette smoking, ingested alcohol is eliminated from 
the body by various metabolic mechanisms, and the alcohol 
elimination process begins almost immediately. Significant 
relationships between excessive drinking and lung cancer have 
been reported whereas appropriate drinking has not shown the 
same effects.24 In terms of alcohol consumption, the subjects 
were classified into the following two groups on the basis of 
their intake for at least 1 year: those who drink more than 20 
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g of alcohol per day (excessive drinkers) and those who drink 
less than 20 g of alcohol per day (appropriate drinkers).
Genotype impact was assessed by a score test for each 
genotype as follows: 0, homozygous for the major allele; 1, 
heterozygous; and 2, homozygous for the minor allele. The 
cumulative “at-risk” genotype (at least one at-risk allele) 
impact was assessed by ordinal scores 0 (no at-risk genotypes), 
1 (one at-risk genotype), 2 (two at-risk genotypes) and 3 (three 
at-risk genotypes). Gene–gene and gene–gene–gene interac-
tions were statistically evaluated on the basis of the likelihood 
test, comparing the models with and without (multiplicative 
scale) terms for interaction.
LD between the CYP1A1 rs4646903 and rs1048943 
polymorphisms was calculated with HaploView software 
(version 4.2, Broad Institute, Cambridge, MA). 25 All statis-
tical analyses were performed using the computer program 
STATA Version 10.1 (STATA Corporation, College Station, 
TX). All p values were two-sided, with those less than 0.05 
considered statistically significant.
RESULTS
The distributions of selected characteristics among sub-
jects are summarized in Table 1. our analysis included 462 
lung cancer patients (242 with adenocarcinoma, 131 with 
squamous cell carcinoma, 69 with small-cell carcinoma, and 
20 with large-cell carcinoma, data not shown). As controls 
were not selected to match lung cancer patients on age and 
sex, there were significant differences in age (p < 0.001) and 
sex ratios (p < 0.001) between lung cancer patients and con-
trols. Compared with control subjects, the lung cancer patients 
were more likely to report a history of smoking (p < 0.001) 
and a history of excessive drinking (p < 0.001). Naturally, 
pack-years of smoking was higher among cases than controls 
(p < 0.001). Lung cancer patients were less likely to be edu-
cated compared to the control subjects (p < 0.001).
Table 2 shows associations between metabolic poly-
morphisms and lung cancer risk. Genotype distributions of 
CYP1A1 rs4646903, CYP1A1 rs1048943 and GSTP1 rs1695 
were consistent with HWE among controls. Among controls, 
the frequency of the CC genotype of CYP1A1 rs4646903 
was 11.4% whereas that of the Val/Val genotype of CYP1A1 
TABLE 1. Selected Characteristics of Lung Cancer Cases and 
Controls
Characteristics Cases (n = 462) Controls (n = 379) p
Ag e (yr), mean  
(95% CI)
66.1 (65.2–66.9) 55.9 (54.6–57.2) <0.001
Sex, n (%)
 Male 287 (62.1) 283 (74.7)
 Female 175 (37.9) 96 (25.3) <0.001
Sm oking status,  
n (%)
 Current smoker 198 (42.9) 129 (34.0)
 Former smoker 111 (24.0) 41 (10.8)
 Never smoker 153 (33.1) 209 (55.2) <0.001
Pa ck-years, mean 
(95% CI)
36.4 (33.3–39.5) 16.0 (13.8–18.2) <0.001
Dri nking status,  
n (%)
284 (61.5) 175 (46.2) <0.001
 Ap propriate 
drinker*
178 (38.5) 204 (53.8)
 Ex cessive  
drinker†
284 (61.5) 175 (46.2) <0.001
Ex posure to 
environmental 
tobacco 
smoke among 
nonsmokers, n (%)
 Positive 99 (64.7) 135 (64.6)
 Negative 54 (35.3) 74 (35.4) 0.982
Education, mean  
 (95% CI)
14.0 (13.8–14.2) 14.9 (14.6–15.1) <0.001
95% CI, 95% confidence interval
* Subjects who drink less than 20 g of alcohol per day.
†   Subjects who drink more than 20 g of alcohol per day.
TABLE 2. Association Between Metabolic Polymorphisms 
and Risk of Lung Cancer
Polymorphism
Cases
n (%) 
Controls
n (%)
Adjusted* 
Odds  
Ratio (95% 
Confidence 
Interval) p
CYP1A1 rs4646903
TT (ancestral†) 148 (32.0) 169 (44.6) 1.0 (reference)
TC 218 (47.2) 167 (44.1) 1.50 (1.06–2.11) 0.021
CC 96 (20.8) 43 (11.4) 2.63 (1.61–4.28) < 0.001
p‡<0.0001 §p = 0.857 p
trend
 < 0.0001
TC + CC vs. TT 1.72 (1.25–2.38) 0.001
CYP1A1 rs1048943
Ile /Ile (AA, 
ancestral†)
248 (53.7) 233 (61.5) 1.0 (reference)
Ile //Val (AG) 160 (34.6) 125 (33.0) 1.18 (0.84–1.66) 0.338
Val/Val (GG) 54 (11.7) 21 (5.54) 2.86 (1.54–5.32) 0.001
p‡ = 0.004 §p = 0.436 p
trend
 = 0.003
Ile /Val + Val/Val 
vs. Ile/Ile
1.40 (1.02–1.92) 0.040
GSTM1 deletion
Non-null 194 (42.0) 194 (51.2) 1.0 (reference)
Null 268 (58.0) 185 (48.8) 1.38 (1.01–1.89) 0.044
p‡ = 0.008
GSTT1 deletion
Non-null 245 (53.0) 215 (56.7) 1.0 (reference)
Null 217 (47.0) 164 (43.3) 1.17 (0.86–1.61) 0.322
p‡ = 0.284
GSTP1 rs1695
Ile/Ile (AA) 323 (69.9) 289 (76.3) 1.0 (reference)
Ile//Val (AG) 120 (26.0) 84 (22.2) 1.37 (0.94–1.97) 0.098
Val/Val (GG, 
 ancestral†)
19 (4.11) 6 (1.58) 3.22 (1.12–9.30) 0.031
p‡ = 0.032 p§ = 0.971 p
trend
 = 0.012
Ile /Val + Val/Val  
vs. Ile/Ile
1.48 (1.04–2.11) 0.031
* Adjusted for age, sex, education, smoking status, and drinking status.
†   Defined by National Center for Biotechnology Information SNP database.
‡   p for χ2 test.
§   p for Hardy-Weinberg equilibrium test among controls.
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TABLE 3. Association Between the Polymorphisms Involved in DNA Repair and Risk of Lung Cancer
Polymorphism
Cases
n (%) 
Controls
n (%) 
Adjusted* Odds Ratio
 (95% Confidence Interval) p
ERCC2 rs13181
Lys/Lys (AA) 332 (71.9) 308 (81.3) 1.0 (reference)
Lys/Gln (AC) 111 (24.0) 65 (17.2) 1.61 (1.07–2.42) 0.022
Gln/Gln (CC, ancestral) 19 (4.11) 6 (1.58) 5.61 (1.99–15.8) 0.001
‡ p = 0.003 §p = 0.240 p
trend
 < 0.0001
Lys/Gln + Gln/Gln vs. Lys/Lys 1.89 (1.28–2.78) 0.001
XRCC1 rs25487 
Arg/Arg (GG, ancestral†) 243 (52.6) 242 (63.9) 1.0 (reference)
Arg/Gln (GA) 171 (37.0) 121 (31.9) 1.38 (0.98–1.94) 0.067
Gln/Gln (AA) 48 (10.4) 16 (4.22) 2.59 (1.36–4.95) 0.004
‡p < 0.0001 §p = 0.859 p
trend
 = 0.002
Arg/Gln + Gln/Gln vs. Arg/Arg 1.54 (1.12–2.13) 0.008
XRCC3 rs861539
Thr/Thr (CC, ancestral†) 352 (76.2) 295 (77.8) 1.0 (reference)
Thr/Met (CT) 97 (21.0) 77 (20.3) 0.95 (0.65–1.39) 0.778
Met/Met (TT) 13 (2.81) 7 (1.85) 1.34 (0.47–3.78) 0.584
‡p  = 0.626 §p = 0.455 p
trend
 = 0.929
Thr/Met + Met/Met vs. Thr/Thr 0.98 (0.68–1.42) 0.915
* Adjusted for age, sex, education, smoking status, and drinking status. 
†   Defined by National Center for Biotechnology Information SNP database.
‡   p for χ2 test.
§   p for Hardy-Weinberg equilibrium test among controls.
rs1048943 was 5.54%. The frequencies of the null genotypes 
of GSTM1 and GSTT1, and the Val/Val genotype of GSTP1 
rs1695 among controls were 48.8%, 43.3%, and 1.58%, 
respectively. After adjustment for age, sex, education, smok-
ing status, and drinking status, the minor homozygotes of the 
CYP1A1 rs4646903 (oR = 2.63, 95% CI = 1.61–4.28, p < 
0.001), CYP1A1 rs1048943 (oR = 2.86, 95% CI = 1.54–5.32, 
p = 0.001) and GSTP1 rs1695 (oR = 3.22, 95% CI = 1.12–
9.30, p = 0.031) polymorphisms were significantly associated 
with an increased lung cancer risk. We excluded pack-years 
(the number of packs of cigarettes smoked/day multiplied by 
years of smoking) from the logistic models because of high 
correlation (pack-year increases with advancing age, corre-
lation coefficient = 0.52, p <0.0001) with age (avoiding the 
problem of potential collinearity). The null genotype of the 
GSTM1 deletion polymorphism was at a 1.38-fold (95% CI = 
1.01–1.89, p = 0.044) increased risk of lung cancer whereas 
the null genotype of the GSTT1 deletion polymorphism was 
not.
Table 3 shows associations between the polymorphisms 
involved in DNA repair and lung cancer risk. The frequencies 
of the minor genotypes of ERCC2 rs13181, XRCC1 rs25487 
and XRCC3 rs861539 among controls were 1.58%, 4.22% and 
1.85%, respectively. ERCC2 rs13181, XRCC1 rs25487, and 
XRCC3 rs861539 polymorphisms did not deviate from HWE 
in controls. An increased risk of lung cancer was seen for sub-
jects carrying either minor homozygote of ERCC2 rs13181 
(oR = 5.61, 95% CI = 1.99–15.8, p = 0.001) or XRCC1 rs25487 
(oR = 2.59, 95% CI = 1.36–4.95, p = 0.004) compared with 
subjects carrying the corresponding major homozygote. The 
minor homozygous genotype of XRCC3 rs861539 was not 
associated with lung cancer risk.
on the basis of our hypothesis, we designated the allele 
that is presumed to increase the risk of lung cancer as the at-risk 
allele. To achieve adequate statistical power, subjects with at least 
one at-risk allele (termed at-risk genotype) were bundled in one 
group for subsequent analysis. Because the CYP1A1 rs4646903 
polymorphism was at LD with the CYP1A1 rs1048943 poly-
morphism (D’ = 0.82, r2 = 0.31, data not shown), rs1048943 
was excluded from the subsequent analysis.
Table 4 shows associations between polymorphisms 
involved in metabolic (the CYP1A1 rs4646903 and GSTM1 
deletion polymorphisms) pathways and three DNA-repair 
pathways (NER, BER and DSBR) and lung cancer risk. 
As for ERCC2 rs13181 (NER)-containing pertinent combina-
tion, multiple at-risk genotypes dose dependently increased 
lung cancer risk (oR = 1.67, 95% CI =1.03–2.72 for one 
at-risk genotype; oR = 1.67, 95% CI =1.03–2.72 for two 
“at-risk” genotypes; oR = 5.94, 95% CI = 2.77–12.7; 
p < 0.001). In the remaining two pertinent combinations, 
increasing numbers of at-risk genotypes also increased lung 
cancer risk in a dose dependent manner (p
trend
 < 0.0001 for 
rs25487; p
trend
 = 0.002 for rs861539). The impact of the 
combination of multiple at-risk genotypes was strongest 
in the combination including ERCC2 rs13181 and weakest 
in the combination including XRCC3 rs861539. No three-
way gene–gene–gene interactions were significant (data not 
shown).
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Table 5 presents the associations between polymor-
phisms involved in metabolic (the CYP1A1 rs4646903 and 
GSTP1 rs1695 polymorphisms) and three DNA-repair path-
ways and lung cancer risk. In three pertinent combinations, 
the risk was more than fourfold in subjects with three at-risk 
genotypes, compared to those with no at-risk genotypes. A 
dose-dependent relationship between lung cancer risk and the 
number of at-risk genotypes was also observed in all pertinent 
combinations. The combination including ERCC2 rs13181 
produced the highest oR (oR = 5.76, 95% CI = 1.69–15.8). 
Three-way gene–gene–gene interactions did not reach statisti-
cal significance (data not shown).
We further examined two-way gene–gene interac-
tions either within one pathway or between two pathways. 
Significant interactions were found between CYP1A1 
rs4646903 and XRCC3 rs861539 (p for interaction = 0.030), 
GSTT1 deletion polymorphism and ERCC2 rs13181 (p 
for interaction = 0.008), and GSTP1 rs1695 and XRCC3 
rs861539 (p for interaction = 0.001). All other two-way 
gene–gene interactions were not statistically significant 
(data not shown).
DISCUSSION
The polymorphisms involved in carcinogen metabo-
lism and DNA repair such as CYP1A1 rs4646903, CYP1A1 
rs1048943, GSTM1 deletion, GSTT1 deletion, GSTP1 rs1695, 
ERCC2 rs13181, XRCC1 rs25487, and XRCC3 rs861539 
were determined in a total of 841 Japanese subjects (462 lung 
cancer cases and 379 controls). The CC (minor) genotype is 
most common among Asians (14%) and least common among 
whites (1.2%) with African-Americans (5.9%) intermediate 
between these groups.26 The prevalence of the CC genotype 
in this control population (11.4%) was similar to that reported 
in other Japanese populations (8.0%,27 10.4%,28 10.6%19 and 
12.9%29). Thus, the minor homozygous genotype in Asians 
was about ten times more than that in whites. The CC geno-
type of CYP1A1 rs4646903 was at a 2.63-fold increased risk 
TABLE 4. Combinations of CYP1A1 rs464903, GSTM1 Deletion Polymorphism and DNA-Repair 
Polymorphisms and Risk of Lung Cancer
Number of “at-risk” genotypes
Cases/
Controls
Adjusted* OR 
(95% CI) p
Adjusted* OR 
(95% CI) pPhase I Phase II
DNA 
Repair
rs4646903 GSTM1 rs13181
0 0 0 44/72 1.0 (reference) 1.0 (reference)
1 0 0 100/81 1.87 (1.09–3.20) 0.023
0 1 0 67/68 1.40 (0.79–2.48) 0.246 1.67 (1.03–2.72) 0.038
0 0 1 15/15 1.96 (0.73–5.27) 0.182
1 1 0 121/87 2.16 (1.27–3.66) 0.004
1 0 1 35/26 2.22 (1.07–4.62) 0.033 2.20 (1.34–3.61) 0.002
0 1 1 22/14 2.43 (1.00–5.87) 0.049
1 1 1 58/16 5.94 (2.77–12.7) <0.001 5.94 (2.77–12.7) <0.001
p
trend
 < 0.001
rs4646903 GSTM1 rs25487
0 0 0 29/54 1.0 (reference) 1.0 (reference)
1 0 0 68/62 1.99 (1.04–3.78) 0.037
0 1 0 55/54 1.48 (0.76–2.89) 0.246 1.71 (0.97–3.03) 0.066
0 0 1 30/33 1.60 (0.74–3.46) 0.228
1 1 0 91/72 2.22 (1.19–4.14) 0.013
1 0 1 67/45 2.29 (1.17–4.50) 0.016 2.23 (1.26–3.95) 0.006
0 1 1 34/28 2.16 (1.00–4.67) 0.050
1 1 1 88/31 4.55 (2.29–9.05) <0.001 4.55 (2.29–9.05) <0.001
p
trend
 < 0.001
rs4646903 GSTM1 rs861539
0 0 0 49/67 1.0 (reference) 1.0 (reference)
1 0 0 100/83 1.58 (0.92–2.73) 0.099
0 1 0 77/59 1.50 (0.84–2.66) 0.171 1.43 (0.88–2.34) 0.150
0 0 1 10/20 0.68 (0.27–1.72) 0.410
1 1 0 126/86 1.95 (1.14–3.31) 0.014
1 0 1 35/24 1.57 (0.77–3.21) 0.214 1.64 (1.00–2.71) 0.050
0 1 1 12/23 0.68 (0.28–1.64) 0.391
1 1 1 53/17 3.41 (1.62–7.19) 0.001 3.41 (1.62–7.19) 0.001
p
trend
 = 0.002
* Adjusted for age, sex, education, smoking status, and drinking status. 
}
}
}
}
}
}
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of lung cancer. Therefore, this association was frequently 
reproduced in Asian populations but not in non-Asian 
populations because of the low prevalence of the C allele 
(low statistical power).30 Substrates for and inducers of 
CyP1A1 include polycyclic aromatic hydrocarbons such 
as benzo(a)pyrene (BP) in tobacco smoke. A genotype-
phenotype association study of CyP1A1 demonstrated that 
the C allele of CYP1A1 rs4646903 is associated with high 
CyP1A1 inducibility.9 Therefore, it is biologically plau-
sible that the CC genotype associated with high enzyme 
activity was related to an increased risk of lung cancer. 
Incidentally, CYP1A1 rs1048943 (Ile462Val) linked to 
CyP1A1 activity,9 and was also shown to be associated 
with lung cancer in a Japanese population.31,32 As shown in 
our study, this polymorphism is closely linked to CYP1A1 
rs4646903.31,33
The phenotypic absence of GSTM1 and GSTT1 activ-
ity is a result of the homozygous deletion of these genes.10,11 
The GSTP1 rs1695 single nucleotide polymorphism (SNP) 
(Ile105Val) is an A (Ile) to G (Val) transition that confers 
reduced catalytic activity.12 The homozygous deletion of the 
GSTM1 gene was shown to occur in approximately 50% of the 
population of various ethnic origins whereas the frequency 
of the GSTT1 null genotype in white populations is 30% or 
less; the frequency of the null genotype in Asian populations 
is similar to that of the GSTM1 null genotype.34 Individuals 
with the Val/Val genotype of GSTP1 rs1695 are most common 
among African-Americans (19%) and least common among 
Japanese (0–3.1%) with whites (6.5–11.7%) intermediate 
between these groups.35 The frequencies of the GST geno-
types were similar to the reported figures in Japanese popu-
lations. In this study, the GSTM1 null genotype and the Val/
Val genotype of GSTP1 rs1695 were significantly associated 
with an increased risk of lung cancer but the GSTT1 null gen-
otype was not. The GSTM1 deletion polymorphism has most 
widely been evaluated for the association with lung cancer 
risk and a significant association was found in both whites 
and Asians in a meta- and pooled analyses.36 However, the 
TABLE 5. Combinations of CYP1A1 rs464903, GSTP1 rs1695 and DNA Repair Polymorphisms and 
Risk of Lung Cancer
Number of “at-risk” genotypes
Cases/
Controls
Adjusted* OR
(95% CI) p
Adjusted* OR
(95% CI) pPhase I Phase II
DNA
Repair
rs4646903 rs1695 rs13181
0 0 0 89/107 1.0 (reference) 1.0 (reference)
1 0 0 149/123 1.49 (0.97– 2.28) 0.066
0 1 0 22/33 0.90 (0.46–1.78) 0.770 1.33 (0.89–1.98) 0.162
0 0 1 21/24 1.11 (0.52–2.41) 0.782
1 1 0 72/45 2.08 (1.21–3.56) 0.008
1 0 1 64/35 2.46 (1.37–4.39) 0.002 2.41 (1.54–3.77) <0.001
0 1 1 16/5 5.85 (1.69–20.2) 0.005
1 1 1 29/7 5.76 (1.69–15.8) 0.001 5.76 (1.69–15.8) 0.001
p
trend
 < 0.001
rs4646903 rs1695 rs25487
0 0 0 57/86 1.0 (reference) 1.0 (reference)
1 0 0 109/102 1.78 (1.09–2.91) 0.022
0 1 0 27/22 1.77 (0.85–3.70) 0.130 1.78 (1.13–2.79) 0.013
0 0 1 53/45 1.77 (0.97–3.22) 0.064
1 1 0 50/32 2.52 (1.32–4.80) 0.005
1 0 1 104/56 2.62 (1.53–4.47) <0.001 2.46 (1.52–3.96) <0.001
0 1 1 11/16 1.62 (0.63–4.16) 0.312
1 1 1 51/20 4.08 (2.02–8.23) <0.001 4.08 (2.02–8.23) <0.001
p
trend
 < 0.001
rs4646903 rs1695 rs861539
0 0 0 95/94 1.0 (reference) 1.0 (reference)
1 0 0 172/124 1.46 (0.95–2.23) 0.083
0 1 0 31/32 1.10 (0.57–2.12) 0.774 1.19 (0.80–1.78) 0.388
0 0 1 15/37 0.43 (0.21–0.90) 0.026
1 1 0 54/45 1.46 (0.83–2.57) 0.193
1 0 1 41/34 1.16 (0.63–2.12) 0.638 1.31 (0.82–2.09) 0.252
0 1 1 7/6 1.30 (0.38–4.41) 0.672
1 1 1 47/7 4.99 (2.04–12.2) <0.001 4.99 (2.04–12.2) <0.001
p
trend
 = 0.002
* Adjusted for age, sex, education, smoking status, and drinking status. 
oR, odds ratio; CI, confidence interval.
}
}
}
}
}
}
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impact of the GSTM1 null genotype was somewhat stronger 
in Asians (oR = 1.33, 95% CI = 1.06–1.67) than whites (oR = 
1.10, 95% CI = 1.01–1.19). In contrast, the deletion GSTT1 
polymorphism has not been suggested to be associated with 
lung cancer in other meta- and pooled analyses.37 In a pooled 
analysis, Asians who carried at least one Val allele of GSTP1 
rs1695 compared with those with the Ile/Ile genotype were 
shown to be at increased risk of lung cancer (oR = 1.35, 95% 
CI = 1.07–1.70).38 The GSTM1 enzyme catalyzes the detoxi-
fication of genotoxins including aromatic hydrocarbon epox-
ides such as BP 7,8-diol 9,10-epoxide (BPDE) and products 
of oxidative stress such as DNA hydroperoxides.39,40 Similarly, 
the GSTP1 enzyme can utilize a variety of potential carcino-
gens, including cigarette-smoke–derived chemicals such as 
BPDE and acrolein.41 The GSTT1 enzyme utilizes potential 
carcinogens including constituents of cigarette smoke such as 
alkyl halides.11 Cigarette smoke is causally related to BPDE-
DNA adduct formation.42,43 BP is metabolically activated to 
BPDE by CyP1A1. Polycyclic aromatic hydrocarbons-DNA 
adducts, especially the BPDE-DNA adduct, have been linked 
to an increased risk of lung cancer.44,45 It is biologically plau-
sible that the genotypes involved in the accumulation of 
BPDE (null genotype of GSTM1 or the Val/Val genotype of 
GSTP1 rs1695) may increase lung cancer risk.
At least four pathways of DNA repair, such as BER, 
NER, mismatch repair, and DSBR, operate on specific types of 
damaged DNA.46 Many studies have investigated the associa-
tions of lung cancer with the genetic polymorphisms involved 
in the BER (repair of small DNA lesions, such as oxidized 
or reduced bases, nonbulky adducts, and DNA single-strand 
break),47 NER (repair of bulky DNA adducts, crosslinks and 
oxidative damages),47 and DSBR pathways in different popu-
lations. Among the known functional genetic polymorphisms 
of the DNA-repair genes, ERCC2 rs13181, XRCC1 rs25487, 
and XRCC3 rs86539 have been studied most commonly. The 
Gln/Gln genotype of ERCC2 rs13181 was common in Europe 
and North America (10%–15%) whereas this genotype was 
uncommon in Asians (about 1%).48 The frequency of the Gln/
Gln genotype in our study was comparable to that in Asian 
studies. Among genetic polymorphisms in the NER pathway, 
an increased risk of lung cancer patients carrying the Gln/Gln 
genotype of ERCC2 rs13181 (Lys751Gln) was found in our 
meta-analysis (oR = 1.30, 95% CI = 1.14–1.49).49 The Gln/
Gln genotype of ERCC2 rs13181 was reported to be associ-
ated with lower DNA-repair capacity.13,14 XRCC1 rs25487 is 
a more common polymorphism than rs1799782 (Arg194Trp) 
and rs25489 (Arg280His), and there was no major variation 
by ethnicity.50 The frequency of the Gln/Gln genotype in our 
study fell within the reported figures (3.3%– 9.4% among 
Asians).50 Among genetic polymorphisms in the BER pathway, 
the Gln/Gln genotype of the XRCC1 rs25487 (Arg399Gln) 
polymorphism was associated with an increased risk of lung 
cancer in our other meta-analysis (oR = 1.34, 95% CI = 
1.16–1.54).51 A significant association between the Gln/Gln 
genotype of XRCC1 rs23487 and decreased DNA capacity has 
been reported.15,16 According to the haplotype map (HapMap) 
SNP database,52 the T allele frequency of rs8615139 is most 
common among whites (42.9%) and least common among 
Han Chinese (5.8%); Japanese (11%) have intermediate 
frequencies. The frequency of the T allele in our study (14%) 
was similar to that in HapMap SNP database. As the Met allele 
of XRCC3 rs861539 (Thr241Met) was significantly associated 
with higher DNA adduct levels, it may be associated with low 
DNA-repair capacity.17 The association between this polymor-
phism and lung cancer risk remains inconsistent, however. As 
the BER and NER pathways play a pivotal role in the removal 
of DNA damage induced by cigarette smoking, it is plausible 
that ERCC2 rs13181 and XRCC1 rs25487 but not XRCC3 
rs81539 were associated with lung cancer risk.
To the best of our knowledge, the association between 
lung cancer risk and the pertinent combination of multiple at-
risk genotypes has not been explored. Individuals who carry 
three at-risk genotypes in the pathways of metabolic and DNA 
repair had a greater risk of developing lung cancer (Tables 4 and 
5). In particular, the pertinent combination of multiple at-risk 
genotypes of CYP1A1 rs4646903, GSTM1 deletion polymor-
phism, and ERCC2 rs13181 was at a 5.94-fold increased risk 
of lung cancer. This finding is biologically plausible because 
CyP1A1, GSTM1, and ERCC2 enzymes are relevant to BPDE-
DNA adduct formation/removal. Similarly, the pertinent com-
bination of multiple at-risk genotypes of CYP1A1 rs4646903, 
GSTP1 rs1695 and ERCC2 rs13181 was at a 5.76-fold increased 
risk of lung cancer. However, the observed oR was slightly 
higher than the expected one (5.94 > 4.49 = 1.72*1.38*1.89 
for GSTM1-containing and 5.76 > 4.81 = 1.72*1.48*1.89 for 
GSTP1-containing). This was just as valid for the remaining com-
binations. This result suggests the absence of gene–gene–gene 
interactions. Although the oR for the combination of CYP1A1 
rs4646903, GSTP1 rs1695, and XRCC3 rs25487 (4.99) was 
twofold higher than the expected oR (2.49 = 1.72*1.48*1.54), 
there is no evidence of interaction. Although the aim of this 
study is to assess the possible association between lung cancer 
risk and the pertinent combination of multiple at-risk genotypes 
in three pathways, we further examined two-way gene–gene 
interactions. Most epidemiological studies on lung cancer have 
considered main effects of single-nucleotide polymorphisms 
or gene-environment interactions and rarely gene–gene 
interactions. Several studies have suggested a possible 
interaction between GSTM1 deletion polymorphism and 
CYP1A1 rs4646903 or rs1048943.53–55 Although we could 
not detect such interactions, the combinations of CYP1A1 
rs4646903 and XRCC3 rs861539, GSTT1 deletion polymor-
phism and ERCC2 rs13181, and GSTP1 rs1695 and XRCC3 
rs861539 showed a significant interaction. Variations in lifestyle 
factors may complicate the validation of the polymorphism–
polymorphism (gene–gene) interactions. Another reason for 
difficulty in validating the gene–gene interactions may be the 
differences in study design and study-sample characteristics 
used. Further studies, which will need to be substantially larger 
than the association studies published to date, are needed to 
validate our findings.
A limitation of our study population was the sample 
size. We cannot exclude chance as an explanation of the sig-
nificant association observed. However, as the minor allele fre-
quency of CYP1A1 rs4646903 is relatively higher in Japanese 
than in other ethnic populations,26 the Japanese are a suitable 
population for study of the role of either CYP1A1 rs4646903 
alone or with other polymorphisms in human carcinogenesis. 
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Case-control studies tend to be susceptible to selection bias, 
particularly in the control group. Controls should represent 
the source population from which the cases were drawn. When 
using hospital-based cases, it may not be possible to define 
the population from which the cases were drawn. Hospital 
controls may be more appropriate because the study popula-
tion can be defined as potential hospital users.56 Generally, the 
reported participation rates were slightly higher in hospital-
based case-control studies than in population-based case-con-
trol studies.57 Participation rates of cases and controls were 
very high in this study. High participation rate may reduce 
the possibility of selection bias.57 However, as the possibil-
ity of selection biases could not be completely excluded in 
case-control studies, our findings should be interpreted with 
caution. The current sample size may prevent any conclusive 
inference. Replication of findings from additional studies with 
larger sample sizes is very important before any causal infer-
ence can be drawn.
In conclusion, the best strategy at present may not be 
a simple combination of multiple at-risk genotypes but a 
pertinent combination of multiple at-risk genotypes that are 
involved in the overall lung carcinogenesis pathway. Although 
lung-cancer–associated polymorphisms should be studied for 
a pertinent combination of multiple at-risk genotypes, no such 
studies have been completed to date. The pertinent combi-
nation of multiple at-risk genotypes of CYP1A1 rs4646903, 
GSTM1 deletion polymorphism, and ERCC2 rs13181 was at 
high risk of lung cancer. This result is biologically plausible 
because CyP1A1, GSTM1, and ERCC2 enzymes are relevant 
to BPDE-DNA adduct formation/removal. However, as at-risk 
genotype combinations are rare in the general population, the 
public-health implications of our finding for primary preven-
tion actions should be carefully considered. Larger studies are 
needed to validate the risk associated with these rare geno-
types that identify at-risk genotypes of metabolic and DNA 
repair as potential contributors to lung cancer risk.
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